Holsboer Florian, Ising Marcus
HMNC Brain Health GmbH, Munich, Germany.
Max Planck Institute of Psychiatry, Munich, Germany.
Handb Clin Neurol. 2021;182:33-48. doi: 10.1016/B978-0-12-819973-2.00003-4.
Stress system dysfunction is a typical characteristic of acute depression and other mood disorders. The exact pattern of factors predisposing for stress-related mental disorders is yet to be unraveled. However, corticosteroid receptor function plays an important role for appropriate or dysfunctional neuroendocrine responses to stress exposure and hence in resilience or risk for the development and course of both, depression and anxiety disorders. Solid neuroscience data strongly support that both neuropeptides, corticotropin-releasing hormone (CRH) and vasopressin (AVP), are central in coordinating humoral and behavioral adaptation to stress. Other neuropeptides, including oxytocin, neuropeptide S, neuropeptide Y, and orexin, are also considered important contributors. Attempts to turn neuropeptide biology into treatments for stress-related disorders need to consider that neuropeptide receptors are specific drug targets for certain patient populations rather than universal targets for all patients, like biogenic amine systems. That is why most negative clinical trials testing neuropeptide receptor antagonists have been in fact failed trials by design, because no companion tests were used to identify which patients with depression are most likely to benefit from a specific neuropeptide receptor-targeting drug treatment. Therefore, the most important future research task is discovery and development of appropriate companion tests that will allow the successful transfer of the precious treasure of neuropeptide system-targeting drugs into clinics.
应激系统功能障碍是急性抑郁症和其他情绪障碍的典型特征。引发应激相关精神障碍的因素的确切模式尚待阐明。然而,皮质类固醇受体功能对于对应激暴露产生适当或功能失调的神经内分泌反应起着重要作用,因此在抑郁症和焦虑症的发生发展过程及恢复力或患病风险方面也起着重要作用。可靠的神经科学数据有力地支持,促肾上腺皮质激素释放激素(CRH)和血管加压素(AVP)这两种神经肽在协调对压力的体液和行为适应方面都起着核心作用。其他神经肽,包括催产素、神经肽S、神经肽Y和食欲素,也被认为是重要的促成因素。将神经肽生物学转化为应激相关疾病治疗方法的尝试需要考虑到,与生物胺系统不同,神经肽受体是某些患者群体的特定药物靶点,而非所有患者的通用靶点。这就是为什么大多数测试神经肽受体拮抗剂的阴性临床试验实际上在设计上就是失败的试验,因为没有使用配套测试来确定哪些抑郁症患者最有可能从特定的神经肽受体靶向药物治疗中获益。因此,未来最重要的研究任务是发现和开发合适的配套测试,这将使神经肽系统靶向药物这一宝贵财富成功应用于临床。